Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients

Pediatric Nephrology

Volumn 10, Issue 1, 1996, Pages 64-66

  Furth, Susan ^a,c   Neu, Alicia ^a   Colombani, Paul ^a   Plotnick, Leslie ^a   Turner, Mary Ellen ^b   Fivush, Barbara ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Diabetes mellitus; Kidney transplantation; Tacrolimus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADOLESCENT; ARTICLE; CASE REPORT; CHILD; DIABETOGENESIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; TACROLIMUS;

EID: 0030033568     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00863448     Document Type: Article

References (13)

1. U.S. Multicenter FK506 Liver Study Group (1994) A comparison of tacrolimus (TK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331:1110-1115
2. Jindal RM (1994) Posttransplant diabetes mellitus - a review. Transplantation 58:1289-1298
3. Friedman EA, Shyh T, Beyer MM, Mania T, Butt KMH (1985) Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 5:196-202
4. Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE (1991) New onset of diabetes in FK506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 23:3169-3170
5. Tzakis A, Reyes J, Todo S, Nour B, Shapiro R, Jordan M, McCauley J, Armitage J, Fung JJ, Starzl TE (1993) Two year experience with FK 506 in pediatric patients. Transplant Proc 25:619-621
6. Klintmalm G (1994) A review of FK506: a new immunosuppressive agent for the prevention and rescue of graft rejection. Transplant Rev 8:53-63
7. Schneck FX, Jordan ML, Jensen CWB, Shapiro R, Tzakis A, Scantlebury V, Ellis E, Gilboa N, Simmons RL, Hakala TR, Starzl TE (1992) Pediatric renal transplantation under FK506 immunosuppression. J Urol 147:1585-1587
8. Ellis D, Shapiro R, Jordan ML, Scantlebury VP, Gilboa N, Hopp L, Weichler N, Tzakis AG, Simmons RL (1994) Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol 8:193-200
9. Starzl TE, Fung J, Jordan M, Shapiro R, Tzakis A, McCauley J, Johnston H, Iwaki Y, Jain A, Alessiani M, Todo S (1990) Kidney transplantation under FK506. JAMA 264:63-67
10. Carroll PB, Rilo H, Reyes J, Alejandro R, Zeng Y, Ricordi C, Tzakis A, Shapiro R, Starzl TE (1991) FK506 associated diabetes mellitus in the pediatric transplant population is a rare complication. Transplant Proc 23:3171-3172
11. Fung J, Alessiani M, Abu-Elmagc K, Todo S, Shapiro R, Tzakis A, Van Thiel D, Armitage J, Jain A, McCauley J, Selby R, Starzl TE (1991) Adverse effects associated with the use of FK506. Transplant Proc 23:3105-3108
12. Krentz AJ, Dousset B, Mayer D, Mcmaster P, Buckels J, Cramb R, Smith JM, Nattrass M (1993) Metabolic effects of cyclosporin A and FK506 in liver transplant recipients. Diabetes 42:1753-1759
13. Jindal RM (1994) Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. Transplantation 58:370-371